The anti-tumor effects of evodiamine on oral squamous cell carcinoma (OSCC) through regulating advanced glycation end products (AGE) / receptor for advanced glycation end products (RAGE) pathway

Evodiamine (EVO) is emerging as a novel anti-tumor drug, which is involved in the inhibition of cell proliferation and apoptosis. High-Mobility Group Box 1 (HMGB1)/RAGE is involved in invasive behavior of OSCC cells and angiogenesis. In this study, we evaluated the potential of EVO in OSCC in vitro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Liuyang, Lou, Ying, Sun, Mingyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806666/
https://www.ncbi.nlm.nih.gov/pubmed/34477479
http://dx.doi.org/10.1080/21655979.2021.1972082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806666/
https://www.ncbi.nlm.nih.gov/pubmed/34477479
http://dx.doi.org/10.1080/21655979.2021.1972082

Ejemplares similares